Tous Actualités
Suivre
Abonner AmVac AG

AmVac AG

V+ invests in AmVac AG

Zug (ots)

The Swiss biopharmaceuticals company AmVac AG in Zug
has joined forces with the long-term strategic investor V+ GmbH & Co 
Fonds 2 KG. The private equity company based in Dresden has invested 
CHF 1,500,000 in AmVac AG since the first half of 2009. Last week V+ 
GmbH & Co Fonds 2 KG announced their intention of acquiring further 
shares in AmVac AG to the sum of CHF 3,000,000.00.
Michael Vogel, spokesman of the investment board: "We agree with 
boosting the holding because our confidence in AmVac AG has continued
to grow. The extremely encouraging prospects described by AmVac for 
vaccines for the indications premature babies and prostatitis have 
convinced us. The experienced management team has also strengthened 
our trust. AmVac have informed us that marketing authorisations for 
the two vaccines FemiVac and ProstaVac are pending all over the 
world, and we are expecting a major return on investment in the 
coming years."
Melinda-Kinga Karpati, CEO of AmVac AG: "In V+ we have found an 
investment company that is going beyond their network to actively 
support us in operative positioning". This gives us enormous drive to
push on with our projects full steam ahead." AmVac AG has also been 
able to convince other renowned private investors such as Dr. Mo 
Ibrahim.
AmVac AG
AmVac AG is a biopharmaceutical company situated in Switzerland. 
The company focuses on the vaccine market with its above-average 
growth figures. There are two therapeutic vaccines in the pipeline 
which are soon to be launched in the fields of gynaecology and 
urology. Further innovative vaccines and technologies are at the 
development stage. The renowned market research company Frost & 
Sullivan awarded AmVac AG the coveted prize "Enabling Technology of 
the Year Award" in 2007.
V+ GmbH & Co Fonds 2 KG
V+ GmbH & Co Fonds 2 KG is one of the leading Venture Capital 
funds that invests in direct shareholdings and secondary market 
holdings in German-speaking countries.

Contact:

Ariane Meynert
Head of PR/IR
E-Mail: meynert@amvac.ch
Tel.: +41/41/725'32'34
Mobile: +41/79/793'34'19

Michael Vogel
V+
E-Mail: vogel@venture-plus.de

Plus de actualités: AmVac AG
Plus de actualités: AmVac AG
  • 14.07.2008 – 14:25

    AmVac AG Expands Its Advisory Board with Hartmut Retzlaff, CEO of STADA Arzneimittel AG

    Zug (ots) - The Swiss company AmVac AG, a biopharmaceutical company based in Zug, has announced the expansion of its Advisory Board. With the acquisition of Hartmut Retzlaff, CEO of STADA Arzneimittel AG, AmVac now has one of the most successful company managers in the German pharmaceutical industry on the Board. Hartmut Retzlaff has been head of STADA AG since 1994 ...

  • 12.06.2008 – 08:50

    AmVac AG Begins Research Cooperation with Bayer

    Zug, Catania (ots) - AmVac AG, a Swiss biopharmaceutical company based in Zug, is starting its first research cooperation program with Bayer Innovation GmbH on the development of a new influenza vaccine. Joint research and development work is beginning with the Bayer subsidiary Icon Genetics GmbH on a novel production approach. Antigens are to be produced for the first time in tobacco plants which along with AmVac AG's ...